Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, talazoparib, which has been approved for NHS use.
The once-daily pill, with its brand name Talzenna and produced by Pfizer, offers a crucial at-home treatment option after receiving a recommendation from the National Institute for Health and Care Excellence (Nice).